# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Nelson Mandela (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML021-SYN-TD
- Date: 2001-04-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Thandiwe Mokoena, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Five-week follow-up after the prostate cancer diagnosis; staging result; radiation oncology seen today. **S**

## History of present illness

Mr. Mandela returns five weeks after his first visit. The PSMA PET/CT two weeks ago showed uptake only in the prostate, with no spread to lymph nodes or bone. He had his DXA scan this morning and then saw Dr. van Zyl of radiation oncology, who went through observation, radiotherapy with short-term androgen deprivation, and surgery with him. He chose radiotherapy to the prostate with six months of androgen deprivation. He starts bicalutamide today and will have his first leuprolide injection at the radiation oncology clinic in one week. Before starting, he was told the expected effects of androgen deprivation (hot flashes, tiredness, loss of libido and erections, weight gain, bone loss, and changes in mood or memory) and how they are monitored. His urinary symptoms are unchanged and mild. He has no bone pain, weight loss, or breathlessness. He starts vitamin D today for the low level found at the first visit. **S**

| Element | Detail |
|---|---|
| Staging | PSMA PET/CT: disease confined to the prostate (N0 M0) |
| Decision | Radiotherapy with six months of androgen deprivation, after radiation oncology consultation today |
| Starting today | Bicalutamide 50 mg daily for four weeks; cholecalciferol 1000 units daily |
| Next step | First leuprolide injection in one week at radiation oncology |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fatigue, weight loss, or night sweats |
| Genitourinary | Positive | Mild urinary frequency, unchanged; no blood in the urine |
| Musculoskeletal | Negative | No bone or back pain |
| Respiratory | Negative | No cough or breathlessness |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |

5 systems reviewed. **S**

## Current medications

- Bicalutamide 50 mg oral tablet, one tablet by mouth once daily for four weeks, to block the testosterone flare at the start of leuprolide **S**
- Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 130/76 mmHg; pulse 66 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 80.4 kg; BMI 24 kg/m². All vital signs are synthetic.

Femoral neck T-score (DXA): -1.4 (low); Lumbar spine T-score (DXA): -0.6; PHQ-2: 0. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Cardiovascular | Regular rhythm; blood pressure 130/76 mm Hg; no ankle swelling |
| Abdomen | Soft; bladder not palpable |
| Musculoskeletal | No spinal tenderness |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Prostate cancer, unfavorable intermediate risk, cT1c N0 M0** (C61). Staging is complete and shows localized disease. The decision for radiotherapy with six months of androgen deprivation follows the radiation oncology consultation and the guidelines for unfavorable intermediate risk in a fit man of his age. **S**
   - Bicalutamide 50 mg daily for four weeks from today.
   - Leuprolide 22.5 mg in one week, then every twelve weeks for a second dose.
   - Fiducial markers and planning scans in about twelve weeks; radiotherapy to start about three months after leuprolide.
2. **Androgen deprivation therapy: baseline** (Z79.899). Baseline testosterone 412 ng/dL, hemoglobin A1c 5.5 percent, LDL 112 mg/dL, and blood pressure 130/76 mm Hg. DXA shows low bone mass at the femoral neck (T-score -1.4) with a normal spine (-0.6). His ten-year hip fracture risk is below the 3 percent treatment threshold, so no bone drug is needed now. Vitamin D was 26 ng/mL. **S**
   - Cholecalciferol 1000 units daily from today.
   - Calcium from food, about 1000 to 1200 mg a day; walking and resistance exercise.
   - PSA, testosterone, and vitamin D in three months; DXA again in one to two years.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | PSA before treatment | At diagnosis, then every 3 to 6 months on androgen deprivation | Up to date | 6.4 ng/mL at the first visit; next on androgen deprivation in three months |
| Laboratory | Testosterone | Baseline, then every 3 to 6 months on androgen deprivation (target below 50 ng/dL) | Up to date | 412 ng/dL at the first visit, before treatment; recheck in three months |
| Laboratory | Hemoglobin A1c or fasting glucose, and lipid panel | Baseline and yearly on androgen deprivation | Up to date | A1c 5.5 percent, glucose 94 mg/dL, LDL 112 mg/dL at the first visit; next in one year |
| Laboratory | Calcium and 25-hydroxyvitamin D | Baseline and periodically on androgen deprivation | Due | Calcium 9.4 mg/dL and vitamin D 26 ng/mL at the first visit; supplement starts today; vitamin D recheck in three months |
| Imaging | Bone density (DXA) | Baseline before androgen deprivation, then every 1 to 2 years | Completed today | Femoral neck T-score -1.4 (low bone mass); lumbar spine -0.6 (normal); hip fracture risk below the treatment threshold |
| Imaging | PSMA PET/CT staging | Once, for unfavorable intermediate or high risk | Up to date | Two weeks ago: no nodal, bone, or visceral disease |
| Examination | Blood pressure and cardiovascular assessment | Every visit on androgen deprivation | Completed today | 130/76 mm Hg; no chest pain or breathlessness; baseline before treatment |
| Survey | Distress and depression screen (PHQ-2) | At diagnosis and at intervals | Completed today | PHQ-2 score 0 |
| Survey | Urinary symptoms (IPSS) | Baseline before treatment, then every follow-up visit | Up to date | IPSS 7 (mild) at the first visit; no change today |
| Survey | Sexual function | Baseline before treatment and periodically | Completed today | Reviewed before androgen deprivation; the expected effects were explained |
| Survey | Cognition | Periodically on androgen deprivation | Due | Cognitive screen at the annual wellness visit in about eight weeks |
| Medication safety | Hot flashes and fatigue | Every visit on androgen deprivation | Not indicated | Androgen deprivation not yet started; counseled on what to expect |
| Medication safety | Testosterone flare protection | When starting a GnRH agonist | Completed today | Bicalutamide starts today, one week before leuprolide, and continues for four weeks |
| Referral | Radiation oncology | Once, then through treatment | Completed today | Seen today; recommendations in the consultation note |
| Self-management | Physical activity, calcium intake, and no tobacco | Every visit | Completed today | Walking every morning; resistance exercise added; dietary calcium reviewed |

## Goal progress

- Reach an informed, shared decision on treatment after hearing every reasonable option, including observation. Outcome by 2001-04-14: Radiotherapy with six months of androgen deprivation chosen at the radiation oncology consultation. **S**
- Complete six months of androgen deprivation and the course of radiotherapy with side effects managed. In progress; target 2001-10-27. **S**
- Protect bone health on androgen deprivation: baseline DXA, vitamin D of 30 ng/mL or more, dietary calcium, and weight-bearing exercise. In progress; target 2001-07-14. **S**
- PSA falling after radiotherapy, with a written surveillance plan. In progress; target 2001-10-27. **S**

## Medication changes

- Started: Bicalutamide 50 mg oral tablet, one tablet by mouth once daily for four weeks, to block the testosterone flare at the start of leuprolide **S**
- Started: Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026), National Comprehensive Cancer Network
- Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol 2022;208(1):10-18 (2022), American Urological Association and American Society for Radiation Oncology
- Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64(4):225-249 (2014), American Cancer Society
- CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026), Aether Forge

## Follow-up

- Leuprolide at radiation oncology in one week. Annual wellness visit in eight weeks. Primary care follow-up in three months with PSA, testosterone, and vitamin D. **S**
- Next scheduled visit 2001-06-09: subsequent annual wellness visit. **S**
